GlassScriptPhysician profile
Vera Lee
NPI 1215437223
$7,499.12
in general payments reported to CMS, 2019-2025
24 companies · $3,269 in 2025
The $3,269 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,579 · 2022: $1,553 · 2023: $362 · 2024: $736 · 2025: $3,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.02 |
| Education | $156.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,662.90 | 2021-2025 | |
| Janssen Biotech, INC. | $780.31 | 2021-2025 | Tremfya |
| Genzyme Corporation | $689.13 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $625.04 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $601.86 | 2021-2025 | Dupixent |
| Incyte Corporation | $488.68 | 2022-2025 | Opzelura, Opzelura |
| Pfizer INC. | $455.80 | 2021-2025 | |
| Galderma Laboratories, L.P. | $327.31 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $290.95 | 2025 | |
| Sun Pharmaceutical Industries INC. | $243.18 | 2021-2024 | |
| Allergan, INC. | $200.33 | 2021-2022 | |
| Amgen INC. | $161.83 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $145.34 | 2021 | |
| Lilly USA, LLC | $131.17 | 2021-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $124.01 | 2022-2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $112.76 | 2024 | Sotyktu |
| Journey Medical Corporation | $99.96 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Ucb, INC. | $76.26 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.21 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Mayne Pharma Commercial LLC | $42.27 | 2021 | |
| Organon LLC | $37.72 | 2025 | Vtama |
| Genentech USA, INC. | $23.59 | 2022 | |
| Epi Health, LLC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.